Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer

2018-02-12 17:45:11 | BioPortfolio

Published on BioPortfolio: 2018-02-12T17:45:11-0500

Clinical Trials [5 Associated Clinical Trials listed on BioPortfolio]

A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib

This study is being done to look at how tucatinib could affect the way other drugs work. This study will look at healthy volunteers and how tucatinib affects their liver enzymes. Liver enz...

Tucatinib (ONT-380) and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer (MOUNTAINEER)

This is a phase II trial that will study how well tucatinib (ONT-380) and trastuzumab work in treating patients with colorectal cancer with a specific genetic marker (human epidermal growt...

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

A phase 2 non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab with capecitabine for the treatment of leptomeningeal metastases in HER2-ne...

A Safety Study of Tucatinib in Healthy and Hepatically-Impaired Subjects

The investigators are doing this study to find out if tucatinib is safe for patients with liver problems. This study will look at participants with mild, moderate, and severe liver problem...

Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer

This is a multicenter run-in phase Ib / roll-over phase II study of triple targeted drug combination (HER2-targeted small molecule inhibitor tucatinib, CDK4/6 inhibitor palbociclib and aro...

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer.

Approximately 30-50% of advanced HER2-positive breast cancer patients will develop central nervous system (CNS) metastases, with an annual risk of around 10%, and a half of them will die from brain pr...

Medical and Biotech [MESH] Definitions

None available.

More From BioPortfolio on "Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer"

Quick Search


Searches Linking to this Trial